Programme

Overview: This symposium is positioned to highlight connections between the DNA damage response and immune responses. DNA damage caused by radiation is known to result in micronuclei due in part to acentrometric DNA fragments that escape normal mitotic segregation. Such micronuclei can recruit pattern recognition receptors such as cGAS, and thereby launch innate immunity signaling pathways that have the potential to boost response to immune therapy. However, much remains unknown about DNA damage sensing and signal transduction, as well as the promise of therapeutic approaches that leverage these responses. In this session, Dr. Shane Harding will provide insights into how DNA damage can affect micronuclei composition and cytokine signaling in response to irradiation. This will be followed by two talks converging on the consequences of ATR/ATM inhibition on immunomodulation. Dr. Randi Syljuåsen will focus on the aspect of apoptotic caspases and their roles in response to low- and high-LET irradiation. Dr. Kevin Harrington will show the latest results of the combination of ATR inhibition with radiotherapy and immunotherapy in animal models and clinical trials. Finally, Dr. Claus Sørensen will delineate how DNA damage checkpoint pathways suppress innate immunity signaling, with consequences for leveraging emerging druggable targets. As such, this session will provide novel insights into DNA damage recognition and signal transduction to immune modulatory pathways, with perspectives on combination treatments that seek to leverage these responses and vulnerabilities.

Overview: This pitch session navigates the cutting edge of adaptive particle therapy, blending physics and clinical perspectives. It spotlights the EU-RAPTOR project's pivotal role in advancing imaging, intervention, and verification, particularly focusing on DIR uncertainty and rapid re-optimization algorithms. Techniques like CBCT/MR to CT and 4DMR are emphasized for their critical contribution to precision and safety in treatment, alongside robust online verification processes. The session compares adaptive photon and proton therapies, highlighting proton therapy's unique challenges and the vital role of multidisciplinary collaboration, patient-centric approaches, and AI integration. It advocates using MRgRT system data to simulate online adaptive radiotherapy in proton therapy. The discussion culminates with an overview of major clinical implementation challenges, such as onboard imaging technology lag, cost considerations, and the necessity for expert verification and rapid, automated planning. The whole session cohesively links technology and clinical practice, underlining their collective significance in progressing real-time adaptive particle therapy and the urgent need for innovative solutions to transition from research to clinical use.

Overview: In this session, our expert speakers will provide comprehensive insights into PROMs, ranging from basic understanding to advanced application in real-world settings. Topics include the fundamentals of PROMs, their selection and content validity, the development of specific patient outcome sets, and the integration of technology with ePROMs. This session is tailored to offer a holistic view of PROMs, highlighting their value in patient care and research, ensuring a rich and diverse learning experience for attendees.

Overview: Reirradiation of prostate cancer addresses a critical aspect of managing recurrent disease post-primary radiotherapy of the prostate. We will evaluate the benefits and limitations of various reirradiation techniques, such as brachytherapy, EBRT, and SBRT, focusing on their effectiveness and potential toxicities. You will be able to focus on selecting suitable reirradiation strategies based on patient selection, precise target delineation, initial treatment modalities, and acute and late GI and GU toxicities. Additionally, the session will explore focal therapy's role in reducing toxicity for recurrent lesions, supported by data and the importance of advanced imaging for targeted reirradiation. We aim to provide a suitable understanding of reirradiation options, enhancing patient care in prostate cancer treatment.

Overview: Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will not be recorded.

Overview: Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will not be recorded.

Overview: Poster Discussions are presented in one of the sessions scheduled at the two poster discussion theatres. Each author will present a digital poster orally for 2 minutes, followed by 2 minutes for discussion. Sessions will not be recorded.